About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The work of our group is mainly focused on personalized medicine, including chemical-functional stability studies of drugs in individualized preparations to be administered both orally and parenterally, as well as parenteral nutrition; research focused on the evaluation and/or design of population pharmacokinetic/pharmacodynamic (PK/PD) models and the characterization of the pharmacokinetics of certain drugs of therapeutic interest in the general population or in certain population groups; and research focused on pharmacogenetics and pharmacogenomics. Our research is also focused on advanced interventions: drug evaluation studies (effectiveness, safety and economic studies); and mobile health and telepharmacy.
IP: Maria Queralt Gorgas Torner
IP: José Raul Herance Camacho Collaborators: Carolina Aparicio Gomez, Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies, Emily Betancourt Fernández, Jana Vidal Otero, Cristina Gamez Cenzano Funding agency: The Innovative Medicines Initiative Funding: 514560 Reference: IMMUNE-IMAGE_IMI22018 Duration: 01/10/2019 - 31/03/2026
IP: Victòria Cardona Dahl Collaborators: Maria Antònia Agustí Escasany, Laura Gomez Ganda Funding agency: Instituto de Salud Carlos III Funding: 30250 Reference: PI19/01656 Duration: 01/01/2020 - 30/06/2024
IP: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE Collaborators: OPTIMIZACIÓN DEL TRATAMIENTO QUIMIOLINFODEPLECTIVO CON FLUDARABINA PREVIO A LA INFUSIÓN DE TERAPIA DE CÉLULAS T CON RECEPTOR DE , Gloria Inés Iacoboni García-Calvo, Maria Queralt Gorgas Torner, Lucas Rivera Sánchez, Anna Maria Farriols Danes, Pere Barba Suñol, Carla Alonso Martinez, Janire Perurena Prieto, Maria Josep Carreras Soler, Cecilia Carmen Carpio Segura Funding agency: Instituto de Salud Carlos III Funding: 111320 Reference: PI21/00197 Duration: 01/01/2022 - 31/12/2024
Within the framework of a clinical trial, the first 3D printed medicine in Europe in the pediatric field will be tested.
